EYEGATE PHARMACEUTICALS INC
Reported by Golden State Wealth Management LLC
Reported 0 shares, down 1,786 (100.0%) from the prior quarter.
Reported value -100.0%; share count -100.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
|
This position's reported history falls outside the five-year preview window. A free account unlocks it.
Unlock full history
|
|||||||
Who else reported the position
15 managers reported EYEGATE PHARMACEUTICALS INC for Q4 2020.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL LLC | Unchanged | 1,815,500 | 0 | 0.3% | $8,950,000 | 6 qtrs |
| BlackRock Inc | Unchanged | 26,235 | 0 | < 0.01% | $129,000 | 6 qtrs |
| VANGUARD GROUP INC | Added | 23,275 | +11,602 | < 0.01% | $115,000 | 3 qtrs |
| GEODE CAPITAL MANAGEMENT LLC | Reduced | 12,656 | -22,374 | < 0.01% | $62,000 | 5 qtrs |
| UBS Group AG | Added | 3,991 | +3,592 | < 0.01% | $20,000 | 5 qtrs |
| US BANCORP DE | Unchanged | 2,710 | 0 | < 0.01% | $13,000 | 6 qtrs |
| ROYAL BANK OF CANADA | Unchanged | 1,690 | 0 | < 0.01% | $8,000 | 6 qtrs |
| Sterling Financial Planning Inc | New | 1,171 | +1,171 | < 0.01% | $6,000 | 1 qtr |
| Tower Research Capital LLC TRC | Reduced | 471 | -971 | < 0.01% | $2,000 | 2 qtrs |
| ADVISOR GROUP HOLDINGS INC | Unchanged | 468 | 0 | < 0.01% | $2,000 | 4 qtrs |
Filing details and methodology As reported
- Report period
- December 31, 2020
- Filed
- January 28, 2021
- Filing type
- 13F-HR
- Position type
- Common Stock
Voting authority reported
No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.